Bruce Vladeck Will Hold Fort (interim) of UMDNJ
Bruce C. Vladeck, an expert in health care policy, is slated to be the interim president of the University of Medicine and Dentistry at New Jersey. Vladeck in an earlier capacity had been in charge of the federal Medicaid and Medicare programs. // Vladeck will now replace UMDNJ president John Petillo, who was eased out of his chair by Gov. Jon Corzine. The Formal relinquishing of author...Interim WHO Chief Confirms 'No radical changes' in WHO
Geneva - The new interim head of the World Health Organization (WHO), Dr Anders Nordstrom, addressing the press for the first time since assuming office // , confirmed that Dr Anders Nordstrom. He also emphasized the need for additional financial resources and the support from the people to continue the fight against HIV/Aids, malaria and polio. He reiterated that he would continue th...Interim OPD saves the day for patients
Medical college and hospital was a scene of pandemonium with protesting students on the one side and junior doctors initiating an outpatients’ department// on the other, causing apparent commotion amongst patients. The groups, under the name of ‘Youth for equality’ are behind these protests. Patients have expressed consolation at the opening of the parallel OPD. A patient Bimal Chandra...Interim Mobile Cardiac Catheterization and Angiography Services
Description:MedCath Diagnostics currently maintains a large number of mobile, modular and transportable cath and vascular labs in its rental fleet. The labs are typically leased to hospitals for several months to several years. The Cath Lab Leasing Company allows hospitals to quickly add capacity while replacing or upgrading existing equipment, initiating a new service and undergoing seasonal volume fluctuat...Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positiveinterim results from the ongoing Phase I study of its leaddevelopment programme, ALX-0081, an anti-thrombotic treatment.ALX-0081 is a novel ´first-in-class´ therapeuticNanobody® targeting von Willebrand Factor (vWF), which canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Pha...